Galectin-3 (LGALS3)
Galectin 3 is a member of the galectin family of β-galactoside-binding proteins and is encoded by LGALS3.
Galectin 3 is a member of the galectin family of β-galactoside-binding proteins and is encoded by LGALS3. It is a multifunctional protein implicated in cell–cell and cell–matrix interactions, immune regulation, inflammation, fibrosis, and tumor biology. In biomedical research, galectin 3 is often discussed as both a circulating biomarker and a mechanistic mediator of disease processes, particularly in settings involving tissue injury, chronic inflammation, metabolic dysfunction, and cancer.
Functionally, galectin 3 has been associated with pathways relevant to metabolic dysfunction–associated steatotic liver disease, Metabolic dysfunction associated steatohepatitis (MASH), cardiovascular injury, and neuroinflammation. It is also studied as a therapeutic target in oncology, where galectin-1 and galectin-3 are sometimes considered together because of their overlapping roles in tumor progression, immune evasion, and the hallmarks of cancer. Recent studies have also linked galectin 3 to disease contexts involving obesity, proinflammatory cytokine signaling, TGF-β1 and VEGF-related fibrotic or angiocrine pathways, Parkinson's disease, and a range of solid tumors.
Where the papers sit
10 papers from the last 6 months study Galectin-3 (LGALS3) directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 1 human data · 6 preclinical · 3 unclassified
Themes 3 themes · 1 new direction
-
Galectin-3 Biomarker Research
Serum and tissue biomarkers are being linked to LGALS3-associated inflammation, apoptosis, and vascular injury across neurologic, renal, and hepatic disease. Multi-omics identifies LGALS3 and VIM in astrocyte responses after traumatic brain injury, while NET–microglia–neutrophil crosstalk is targeted in retinal angiogenesis. Soluble glial markers are also being tested against radiologic outcomes in multiple sclerosis and mortality in hemodialysis. The field is moving toward integrated biomarker panels, but disease-specific validation and causal utility remain unresolved.
5 papers · 50%
-
Endometrial Endocrine Remodeling
Tamoxifen and progesterone receptor modulators produce distinct LGALS3 responses in endometrial adenocarcinoma models. Mifepristone and ulipristal acetate are examined alongside tamoxifen to connect endocrine therapy with endometrial remodeling. The recurring clinical question is whether LGALS3 can mark or mediate treatment-associated endometrial change. Validation beyond Ishikawa-cell and computational studies remains open.
2 papers · 20%
-
Others — Galectin-3 Translational Research
Galectin-3 targeting appears across aggressive meningioma, modular theranostic design, and MASH-associated muscle atrophy. Meningioma work combines Galectin-3 inhibition with transcranial direct-current stimulation. Other work treats Galectin-3 as a targeting moiety or examines hepatokine-driven wasting. These applications share a molecule more than a disease or mechanism, so no common therapeutic direction is established.
3 papers · 30%
Galectin-3 is repurposed as a tumor-targeting moiety rather than a disease mediator, biomarker, or therapeutic target
The coil-coiled theranostic system for tumor xenografts uses truncated human Galectin-3 as the targeting component, exploiting its binding to β-galactoside-containing oligosaccharides on tumor-cell membranes to deliver biotinylated doxorubicin. This assigns LGALS3 a carrier-and-recognition role in drug delivery, rather than the biomarker, pathogenic mediator, or inhibited target roles used by the other studies, opening a modular strategy in which the Galectin-3 targeting moiety can direct therapeutic cargo to ligand-expressing tumors 42363882Jun.
Papers
The 10 papers from the last 6 months that study Galectin-3 (LGALS3) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Galectin-3 Biomarker Research (5)
- Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation · 15 Oct 2026 PMID 42879711
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- Multi-omics integration identifies VIM and LGALS3 as apoptosis-associated genes in astrocytes after traumatic brain injury. Neuroscience · 19 Aug 2026 PMID 42617790
- Disrupting galectin-3 and NET-mediated microglia-neutrophil cross-talk suppresses pathological retinal angiogenesis. Science translational medicine · 5 Aug 2026 PMID 42555755
- Biomarkers in predicting mortality in hemodialysis patients: recent advances. Polish archives of internal medicine · 15 Jul 2026 PMID 42455729
Endometrial Endocrine Remodeling (2)
- Differential Modulation of Galectin-3 by Tamoxifen and Progesterone Receptor Modulators: An In Vitro and In Silico Study. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957243
- Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957240
Others — Galectin-3 Translational Research (3)
- Effects of Galectin-3 inhibitors paired with direct current stimulation in preclinical models of aggressive meningioma. Molecular biology reports · 27 Jun 2026 PMID 42363999
- Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules · 27 Jun 2026 PMID 42363882
- Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH. Molecular metabolism · 10 Jun 2026 PMID 42270040
By study type
Human data, design not indexed (1)
- Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis. Neurology(R) neuroimmunology & neuroinflammation · 15 Oct 2026 PMID 42879711
Preclinical: animal, cell and lab studies (6)
- Differential Modulation of Galectin-3 by Tamoxifen and Progesterone Receptor Modulators: An In Vitro and In Silico Study. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957243
- Galectin-3 as a Candidate Marker of Endocrine-modulator-associated Endometrial Remodeling During Breast Cancer Endocrine Therapy. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957240
- Bellidifolin alleviates doxorubicin-induced hepatotoxicity: a study integrating network pharmacology, molecular docking, and experimental validation. Die Naturwissenschaften · 22 Sept 2026 PMID 42771163
- Disrupting galectin-3 and NET-mediated microglia-neutrophil cross-talk suppresses pathological retinal angiogenesis. Science translational medicine · 5 Aug 2026 PMID 42555755
- Effects of Galectin-3 inhibitors paired with direct current stimulation in preclinical models of aggressive meningioma. Molecular biology reports · 27 Jun 2026 PMID 42363999
- Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules · 27 Jun 2026 PMID 42363882
Unclassified: not yet indexed with MeSH (3)
- Multi-omics integration identifies VIM and LGALS3 as apoptosis-associated genes in astrocytes after traumatic brain injury. Neuroscience · 19 Aug 2026 PMID 42617790
- Biomarkers in predicting mortality in hemodialysis patients: recent advances. Polish archives of internal medicine · 15 Jul 2026 PMID 42455729
- Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH. Molecular metabolism · 10 Jun 2026 PMID 42270040
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-24 by GPT. Drafted by language models from published abstracts; not medical advice.